The Long Noncoding RNA CCAT2 Induces Chromosomal Instability Through BOP1-AURKB Signaling.


Journal

Gastroenterology
ISSN: 1528-0012
Titre abrégé: Gastroenterology
Pays: United States
ID NLM: 0374630

Informations de publication

Date de publication:
12 2020
Historique:
received: 20 08 2019
revised: 10 08 2020
accepted: 11 08 2020
pubmed: 18 8 2020
medline: 16 4 2021
entrez: 18 8 2020
Statut: ppublish

Résumé

Chromosomal instability (CIN) is a carcinogenesis event that promotes metastasis and resistance to therapy by unclear mechanisms. Expression of the colon cancer-associated transcript 2 gene (CCAT2), which encodes a long noncoding RNA (lncRNA), associates with CIN, but little is known about how CCAT2 lncRNA regulates this cancer enabling characteristic. We performed cytogenetic analysis of colorectal cancer (CRC) cell lines (HCT116, KM12C/SM, and HT29) overexpressing CCAT2 and colon organoids from C57BL/6N mice with the CCAT2 transgene and without (controls). CRC cells were also analyzed by immunofluorescence microscopy, γ-H2AX, and senescence assays. CCAT2 transgene and control mice were given azoxymethane and dextran sulfate sodium to induce colon tumors. We performed gene expression array and mass spectrometry to detect downstream targets of CCAT2 lncRNA. We characterized interactions between CCAT2 with downstream proteins using MS2 pull-down, RNA immunoprecipitation, and selective 2'-hydroxyl acylation analyzed by primer extension analyses. Downstream proteins were overexpressed in CRC cells and analyzed for CIN. Gene expression levels were measured in CRC and non-tumor tissues from 5 cohorts, comprising more than 900 patients. High expression of CCAT2 induced CIN in CRC cell lines and increased resistance to 5-fluorouracil and oxaliplatin. Mice that expressed the CCAT2 transgene developed chromosome abnormalities, and colon organoids derived from crypt cells of these mice had a higher percentage of chromosome abnormalities compared with organoids from control mice. The transgenic mice given azoxymethane and dextran sulfate sodium developed more and larger colon polyps than control mice given these agents. Microarray analysis and mass spectrometry indicated that expression of CCAT2 increased expression of genes involved in ribosome biogenesis and protein synthesis. CCAT2 lncRNA interacted directly with and stabilized BOP1 ribosomal biogenesis factor (BOP1). CCAT2 also increased expression of MYC, which activated expression of BOP1. Overexpression of BOP1 in CRC cell lines resulted in chromosomal missegregation errors, and increased colony formation, and invasiveness, whereas BOP1 knockdown reduced viability. BOP1 promoted CIN by increasing the active form of aurora kinase B, which regulates chromosomal segregation. BOP1 was overexpressed in polyp tissues from CCAT2 transgenic mice compared with healthy tissue. CCAT2 lncRNA and BOP1 mRNA or protein were all increased in microsatellite stable tumors (characterized by CIN), but not in tumors with microsatellite instability compared with nontumor tissues. Increased levels of CCAT2 lncRNA and BOP1 mRNA correlated with each other and with shorter survival times of patients. We found that overexpression of CCAT2 in colon cells promotes CIN and carcinogenesis by stabilizing and inducing expression of BOP1 an activator of aurora kinase B. Strategies to target this pathway might be developed for treatment of patients with microsatellite stable colorectal tumors.

Sections du résumé

BACKGROUND & AIMS
Chromosomal instability (CIN) is a carcinogenesis event that promotes metastasis and resistance to therapy by unclear mechanisms. Expression of the colon cancer-associated transcript 2 gene (CCAT2), which encodes a long noncoding RNA (lncRNA), associates with CIN, but little is known about how CCAT2 lncRNA regulates this cancer enabling characteristic.
METHODS
We performed cytogenetic analysis of colorectal cancer (CRC) cell lines (HCT116, KM12C/SM, and HT29) overexpressing CCAT2 and colon organoids from C57BL/6N mice with the CCAT2 transgene and without (controls). CRC cells were also analyzed by immunofluorescence microscopy, γ-H2AX, and senescence assays. CCAT2 transgene and control mice were given azoxymethane and dextran sulfate sodium to induce colon tumors. We performed gene expression array and mass spectrometry to detect downstream targets of CCAT2 lncRNA. We characterized interactions between CCAT2 with downstream proteins using MS2 pull-down, RNA immunoprecipitation, and selective 2'-hydroxyl acylation analyzed by primer extension analyses. Downstream proteins were overexpressed in CRC cells and analyzed for CIN. Gene expression levels were measured in CRC and non-tumor tissues from 5 cohorts, comprising more than 900 patients.
RESULTS
High expression of CCAT2 induced CIN in CRC cell lines and increased resistance to 5-fluorouracil and oxaliplatin. Mice that expressed the CCAT2 transgene developed chromosome abnormalities, and colon organoids derived from crypt cells of these mice had a higher percentage of chromosome abnormalities compared with organoids from control mice. The transgenic mice given azoxymethane and dextran sulfate sodium developed more and larger colon polyps than control mice given these agents. Microarray analysis and mass spectrometry indicated that expression of CCAT2 increased expression of genes involved in ribosome biogenesis and protein synthesis. CCAT2 lncRNA interacted directly with and stabilized BOP1 ribosomal biogenesis factor (BOP1). CCAT2 also increased expression of MYC, which activated expression of BOP1. Overexpression of BOP1 in CRC cell lines resulted in chromosomal missegregation errors, and increased colony formation, and invasiveness, whereas BOP1 knockdown reduced viability. BOP1 promoted CIN by increasing the active form of aurora kinase B, which regulates chromosomal segregation. BOP1 was overexpressed in polyp tissues from CCAT2 transgenic mice compared with healthy tissue. CCAT2 lncRNA and BOP1 mRNA or protein were all increased in microsatellite stable tumors (characterized by CIN), but not in tumors with microsatellite instability compared with nontumor tissues. Increased levels of CCAT2 lncRNA and BOP1 mRNA correlated with each other and with shorter survival times of patients.
CONCLUSIONS
We found that overexpression of CCAT2 in colon cells promotes CIN and carcinogenesis by stabilizing and inducing expression of BOP1 an activator of aurora kinase B. Strategies to target this pathway might be developed for treatment of patients with microsatellite stable colorectal tumors.

Identifiants

pubmed: 32805281
pii: S0016-5085(20)35057-5
doi: 10.1053/j.gastro.2020.08.018
pmc: PMC7725986
mid: NIHMS1622361
pii:
doi:

Substances chimiques

BOP1 protein, human 0
Dextrans 0
MYC protein, human 0
Proto-Oncogene Proteins c-myc 0
RNA, Long Noncoding 0
RNA-Binding Proteins 0
long non-coding RNA CCAT2, human 0
AURKB protein, human EC 2.7.11.1
Aurora Kinase B EC 2.7.11.1
Azoxymethane MO0N1J0SEN

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

2146-2162.e33

Subventions

Organisme : NIGMS NIH HHS
ID : R35 GM126942
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA202797
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA096297
Pays : United States
Organisme : NCATS NIH HHS
ID : UH3 TR000943
Pays : United States
Organisme : NCI NIH HHS
ID : R50 CA211121
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA096300
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM121487
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA072851
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA182905
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA222007
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA051008
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM122775
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA181572
Pays : United States
Organisme : NCI NIH HHS
ID : R50 CA243707
Pays : United States

Informations de copyright

Copyright © 2020 AGA Institute. Published by Elsevier Inc. All rights reserved.

Références

Nat Med. 2011 Oct 23;17(11):1514-20
pubmed: 22019887
Cancer Inform. 2017 Dec 13;16:1176935117746637
pubmed: 29343938
Semin Cancer Biol. 2007 Feb;17(1):5-18
pubmed: 17126026
Nat Rev Genet. 2012 Jan 24;13(3):189-203
pubmed: 22269907
Chromosoma. 2013 Dec;122(6):487-97
pubmed: 24022641
Nature. 1994 Sep 22;371(6495):297-300
pubmed: 8090199
Genome Res. 2018 Apr;28(4):432-447
pubmed: 29567676
Biochim Biophys Acta. 2009 Oct;1790(10):963-9
pubmed: 19344750
Genome Res. 2002 Jun;12(6):996-1006
pubmed: 12045153
Proc Natl Acad Sci U S A. 2014 Sep 23;111(38):E3996-4005
pubmed: 25201961
Clin Cancer Res. 2011 Mar 15;17(6):1218-22
pubmed: 21288923
Nat Genet. 2006 Sep;38(9):1043-8
pubmed: 16921376
Cold Spring Harb Perspect Biol. 2012 Nov 01;4(11):
pubmed: 22888049
Ann Oncol. 2013 Aug;24(8):2048-56
pubmed: 23532114
Genes Chromosomes Cancer. 2006 Sep;45(9):874-81
pubmed: 16804918
N Engl J Med. 2017 Jun 1;376(22):2109-2121
pubmed: 28445112
Blood. 2010 Sep 2;116(9):1498-505
pubmed: 20519624
Mol Cell Biol. 2007 May;27(10):3682-94
pubmed: 17353269
Nat Rev Mol Cell Biol. 2010 Mar;11(3):220-8
pubmed: 20177397
Genome Res. 2013 Sep;23(9):1446-61
pubmed: 23796952
Cell. 2018 Sep 6;174(6):1347-1360
pubmed: 30193109
Eur J Haematol. 2015 Jul;95(1):3-15
pubmed: 25645650
Nature. 2014 Sep 11;513(7517):202-9
pubmed: 25079317
Nat Rev Mol Cell Biol. 2012 Dec;13(12):789-803
pubmed: 23175282
J Biol Chem. 2004 Mar 26;279(13):12997-3003
pubmed: 14722118
Nature. 2010 Feb 18;463(7283):899-905
pubmed: 20164920
PLoS One. 2011;6(7):e22114
pubmed: 21799775
Gut. 2016 Oct;65(10):1690-701
pubmed: 26156959
Cancer Res. 2018 Dec 1;78(23):6529-6535
pubmed: 30420473
J Clin Oncol. 2012 Jun 20;30(18):2256-64
pubmed: 22547595
Chromosoma. 2004 Jun;112(8):389-97
pubmed: 15156327
Gut. 2020 Apr;69(4):748-763
pubmed: 32034004
PLoS One. 2014 Jun 26;9(6):e100748
pubmed: 24968351
Oncogene. 2004 Nov 11;23(53):8597-602
pubmed: 15467761
Oncotarget. 2014 Feb 28;5(4):860-71
pubmed: 24658219
Mol Cell. 2016 Feb 18;61(4):520-534
pubmed: 26853146
BMC Cancer. 2008 Oct 29;8:314
pubmed: 18959792

Auteurs

Baoqing Chen (B)

Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China; Department of Thoracic Oncology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

Mihnea P Dragomir (MP)

Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas; Department of General Surgery, Fundeni Clinical Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.

Linda Fabris (L)

Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Recep Bayraktar (R)

Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Erik Knutsen (E)

Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Medical Biology, Faculty of Health Sciences, The Arctic University of Norway, Tromsø, Norway.

Xu Liu (X)

Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Thoracic Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.

Changyan Tang (C)

Department of Chemistry, University of Washington, Seattle, Washington.

Yongfeng Li (Y)

Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Tadanobu Shimura (T)

Center for Gastrointestinal Research; Center for Translational Genomics and Oncology, Baylor Scott & White Research Institute, Charles A Sammons Cancer Center, Baylor University Medical Center, Dallas, Texas.

Tina Catela Ivkovic (TC)

Central European Institute of Technology, Masaryk University, Brno, Czech Republic.

Mireia Cruz De Los Santos (MC)

Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Simone Anfossi (S)

Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Masayoshi Shimizu (M)

Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Maitri Y Shah (MY)

Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Hui Ling (H)

Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Peng Shen (P)

Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.

Asha S Multani (AS)

Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Barbara Pardini (B)

Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Jared K Burks (JK)

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Hiroyuki Katayama (H)

Department of Clinical Cancer Prevention, University of Texas MD Anderson Cancer Center, Houston, Texas.

Lucas C Reineke (LC)

Department of Neuroscience, Baylor College of Medicine, Houston, Texas.

Longfei Huo (L)

Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Muddassir Syed (M)

Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.

Shumei Song (S)

Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Manuela Ferracin (M)

Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.

Eiji Oki (E)

Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Bastian Fromm (B)

Science for Life Laboratory, Department of Molecular Biosciences, The Wenner-Gren Institute, Stockholm University, Stockholm, Sweden; Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.

Cristina Ivan (C)

Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas; Center for RNA Interference and Non-Coding RNAs, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Krithika Bhuvaneshwar (K)

Innovation Center for Biomedical Informatics, Georgetown University, Washington, District of Columbia.

Yuriy Gusev (Y)

Innovation Center for Biomedical Informatics, Georgetown University, Washington, District of Columbia.

Koshi Mimori (K)

Department of Surgery, Kyushu University Beppu Hospital, Beppu, Japan.

David Menter (D)

Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Subrata Sen (S)

Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Takatoshi Matsuyama (T)

Department of Gastrointestinal Surgery, Tokyo Medical and Dental University Graduate School of Medicine, Tokyo, Japan.

Hiroyuki Uetake (H)

Department of Specialized Surgeries, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan.

Catalin Vasilescu (C)

Department of General Surgery, Fundeni Clinical Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.

Scott Kopetz (S)

Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Jan Parker-Thornburg (J)

Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Ayumu Taguchi (A)

Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Samir M Hanash (SM)

Department of Clinical Cancer Prevention, University of Texas MD Anderson Cancer Center, Houston, Texas.

Leonard Girnita (L)

Department of Oncology-Pathology, Bioclinicum, Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden.

Ondrej Slaby (O)

Central European Institute of Technology, Masaryk University, Brno, Czech Republic; Department of Biology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.

Ajay Goel (A)

Center for Gastrointestinal Research; Center for Translational Genomics and Oncology, Baylor Scott & White Research Institute, Charles A Sammons Cancer Center, Baylor University Medical Center, Dallas, Texas.

Gabriele Varani (G)

Department of Chemistry, University of Washington, Seattle, Washington.

Mihai Gagea (M)

Department of Veterinary Medicine and Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Chunlai Li (C)

Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: CLi10@mdanderson.org.

Jaffer A Ajani (JA)

Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: jajani@mdanderson.org.

George A Calin (GA)

Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas; Center for RNA Interference and Non-Coding RNAs, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: gcalin@mdanderson.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH